E
Eterna Therapeutics D
D
ERNA
0.19070
USD
-0.01
(-4.84%)
Market Closed
Volume
4,300
EPS
-11
Div Yield
-
P/E
-0
Market Cap
5,559,750
Title: Ernexa Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.